HRP20050568A2 - Haplotype partitioning - Google Patents
Haplotype partitioning Download PDFInfo
- Publication number
- HRP20050568A2 HRP20050568A2 HR20050568A HRP20050568A HRP20050568A2 HR P20050568 A2 HRP20050568 A2 HR P20050568A2 HR 20050568 A HR20050568 A HR 20050568A HR P20050568 A HRP20050568 A HR P20050568A HR P20050568 A2 HRP20050568 A2 HR P20050568A2
- Authority
- HR
- Croatia
- Prior art keywords
- image
- haplotype
- haplotypes
- gene
- snps
- Prior art date
Links
- 102000054766 genetic haplotypes Human genes 0.000 title claims description 182
- 238000000638 solvent extraction Methods 0.000 title description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 68
- 238000000034 method Methods 0.000 claims description 41
- 102000054765 polymorphisms of proteins Human genes 0.000 claims description 27
- 230000035772 mutation Effects 0.000 claims description 23
- 102000004169 proteins and genes Human genes 0.000 claims description 21
- 239000012634 fragment Substances 0.000 claims description 19
- 238000004458 analytical method Methods 0.000 claims description 15
- 238000012360 testing method Methods 0.000 claims description 13
- 239000002773 nucleotide Substances 0.000 claims description 11
- 125000003729 nucleotide group Chemical group 0.000 claims description 11
- 238000000926 separation method Methods 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 238000001514 detection method Methods 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- 238000003745 diagnosis Methods 0.000 claims description 2
- 230000014509 gene expression Effects 0.000 description 84
- 108700028369 Alleles Proteins 0.000 description 37
- 210000004027 cell Anatomy 0.000 description 27
- 230000000694 effects Effects 0.000 description 27
- 101150009271 gh1 gene Proteins 0.000 description 26
- 238000000338 in vitro Methods 0.000 description 17
- 108060001084 Luciferase Proteins 0.000 description 14
- 239000005089 Luciferase Substances 0.000 description 13
- 238000002337 electrophoretic mobility shift assay Methods 0.000 description 12
- 239000013615 primer Substances 0.000 description 12
- 108010051696 Growth Hormone Proteins 0.000 description 10
- 102100038803 Somatotropin Human genes 0.000 description 10
- 239000000122 growth hormone Substances 0.000 description 10
- 108091034117 Oligonucleotide Proteins 0.000 description 9
- 108700008625 Reporter Genes Proteins 0.000 description 9
- 238000003556 assay Methods 0.000 description 9
- 101150054854 POU1F1 gene Proteins 0.000 description 8
- 101100297347 Caenorhabditis elegans pgl-3 gene Proteins 0.000 description 7
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 7
- 108091023040 Transcription factor Proteins 0.000 description 7
- 102000040945 Transcription factor Human genes 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 230000001817 pituitary effect Effects 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 6
- 239000013642 negative control Substances 0.000 description 6
- 230000002103 transcriptional effect Effects 0.000 description 6
- 108700009124 Transcription Initiation Site Proteins 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 102000009310 vitamin D receptors Human genes 0.000 description 4
- 108050000156 vitamin D receptors Proteins 0.000 description 4
- 108091026890 Coding region Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101100149846 Homo sapiens GH1 gene Proteins 0.000 description 3
- 108010023243 NFI Transcription Factors Proteins 0.000 description 3
- 102000011178 NFI Transcription Factors Human genes 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 238000002741 site-directed mutagenesis Methods 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 206010062767 Hypophysitis Diseases 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 238000007476 Maximum Likelihood Methods 0.000 description 2
- 108010086093 Mung Bean Nuclease Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 102100024819 Prolactin Human genes 0.000 description 2
- 108010057464 Prolactin Proteins 0.000 description 2
- 101100540673 Rattus norvegicus Gc gene Proteins 0.000 description 2
- 208000020221 Short stature Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 238000000376 autoradiography Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000009699 differential effect Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 230000007614 genetic variation Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 210000003635 pituitary gland Anatomy 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 229940097325 prolactin Drugs 0.000 description 2
- 230000006916 protein interaction Effects 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 238000000611 regression analysis Methods 0.000 description 2
- 238000005204 segregation Methods 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000007492 two-way ANOVA Methods 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 108020003589 5' Untranslated Regions Proteins 0.000 description 1
- 102100021809 Chorionic somatomammotropin hormone 1 Human genes 0.000 description 1
- 102100038530 Chorionic somatomammotropin hormone 2 Human genes 0.000 description 1
- 102100031633 Chorionic somatomammotropin hormone-like 1 Human genes 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 238000003718 Dual-Luciferase Reporter Assay System Methods 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000895818 Homo sapiens Chorionic somatomammotropin hormone 1 Proteins 0.000 description 1
- 101000956228 Homo sapiens Chorionic somatomammotropin hormone 2 Proteins 0.000 description 1
- 101000940558 Homo sapiens Chorionic somatomammotropin hormone-like 1 Proteins 0.000 description 1
- 101001075374 Homo sapiens Gamma-glutamyl hydrolase Proteins 0.000 description 1
- 101000642577 Homo sapiens Growth hormone variant Proteins 0.000 description 1
- 101000687438 Homo sapiens Prolactin Proteins 0.000 description 1
- 101000664737 Homo sapiens Somatotropin Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 101150083321 Nf1 gene Proteins 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 241000242739 Renilla Species 0.000 description 1
- 238000003646 Spearman's rank correlation coefficient Methods 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 108700026226 TATA Box Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000002547 anomalous effect Effects 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000002790 cross-validation Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000012631 diagnostic technique Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 108010084724 gibbon ape leukemia virus receptor Proteins 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- 238000003468 luciferase reporter gene assay Methods 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 102000044158 nucleic acid binding protein Human genes 0.000 description 1
- 108700020942 nucleic acid binding protein Proteins 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000003571 reporter gene assay Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Separation By Low-Temperature Treatments (AREA)
- Saccharide Compounds (AREA)
- Exchange Systems With Centralized Control (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0229725.7A GB0229725D0 (en) | 2002-12-19 | 2002-12-19 | Haplotype partitioning and growth hormone SNPs |
| PCT/GB2003/005412 WO2004057029A2 (en) | 2002-12-19 | 2003-12-11 | Haplotype partitioning |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20050568A2 true HRP20050568A2 (en) | 2005-10-31 |
Family
ID=9950092
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20050568A HRP20050568A2 (en) | 2002-12-19 | 2005-06-17 | Haplotype partitioning |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20060121486A1 (zh) |
| EP (1) | EP1581655A2 (zh) |
| JP (1) | JP2007515921A (zh) |
| KR (1) | KR20050075450A (zh) |
| CN (2) | CN1726289A (zh) |
| AU (1) | AU2003290250A1 (zh) |
| CA (1) | CA2506535A1 (zh) |
| GB (1) | GB0229725D0 (zh) |
| HR (1) | HRP20050568A2 (zh) |
| NO (1) | NO20053499L (zh) |
| RU (1) | RU2005118399A (zh) |
| WO (1) | WO2004057029A2 (zh) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2787971A4 (en) | 2012-02-22 | 2015-04-29 | Duchesnay Inc | FORMULATION OF DOXYLAMINE AND PYRIDOXINE AND / OR THEIR METABOLITES OR SALTS |
| MX366760B (es) | 2013-07-22 | 2019-07-23 | Duchesnay Inc | Composición para la gestión de las náuseas y los vómitos. |
| CN106652707A (zh) * | 2017-02-21 | 2017-05-10 | 樊郁兰 | 用于模拟中学生物教学中dna二级结构的方法及其装置 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2197408A1 (en) * | 1996-02-13 | 1997-08-14 | Kazuo Chihara | Mutant human growth hormones and their uses |
-
2002
- 2002-12-19 GB GBGB0229725.7A patent/GB0229725D0/en not_active Ceased
-
2003
- 2003-12-11 CA CA002506535A patent/CA2506535A1/en not_active Abandoned
- 2003-12-11 RU RU2005118399/13A patent/RU2005118399A/ru not_active Application Discontinuation
- 2003-12-11 US US10/539,953 patent/US20060121486A1/en not_active Abandoned
- 2003-12-11 KR KR1020057009845A patent/KR20050075450A/ko not_active Application Discontinuation
- 2003-12-11 AU AU2003290250A patent/AU2003290250A1/en not_active Abandoned
- 2003-12-11 EP EP03782615A patent/EP1581655A2/en not_active Withdrawn
- 2003-12-11 JP JP2004561614A patent/JP2007515921A/ja not_active Withdrawn
- 2003-12-11 CN CNA2003801065037A patent/CN1726289A/zh active Pending
- 2003-12-11 WO PCT/GB2003/005412 patent/WO2004057029A2/en not_active Application Discontinuation
- 2003-12-11 CN CNA2003801067422A patent/CN1729300A/zh active Pending
-
2005
- 2005-06-17 HR HR20050568A patent/HRP20050568A2/hr not_active Application Discontinuation
- 2005-07-18 NO NO20053499A patent/NO20053499L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| RU2005118399A (ru) | 2006-02-10 |
| CN1729300A (zh) | 2006-02-01 |
| CN1726289A (zh) | 2006-01-25 |
| NO20053499L (no) | 2005-07-18 |
| KR20050075450A (ko) | 2005-07-20 |
| WO2004057029A2 (en) | 2004-07-08 |
| EP1581655A2 (en) | 2005-10-05 |
| US20060121486A1 (en) | 2006-06-08 |
| CA2506535A1 (en) | 2004-07-08 |
| WO2004057029A3 (en) | 2004-08-12 |
| GB0229725D0 (en) | 2003-01-29 |
| JP2007515921A (ja) | 2007-06-21 |
| AU2003290250A1 (en) | 2004-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Deutsch et al. | Gene expression variation and expression quantitative trait mapping of human chromosome 21 genes | |
| Barcellos et al. | High-density SNP screening of the major histocompatibility complex in systemic lupus erythematosus demonstrates strong evidence for independent susceptibility regions | |
| Dai et al. | Probing nucleosome function: a highly versatile library of synthetic histone H3 and H4 mutants | |
| Samaco et al. | Epigenetic overlap in autism-spectrum neurodevelopmental disorders: MECP2 deficiency causes reduced expression of UBE3A and GABRB3 | |
| Asselta et al. | X chromosome contribution to the genetic architecture of primary biliary cholangitis | |
| AU2003245488A8 (en) | Functional sites | |
| Bryant et al. | Reduced complexity cross design for behavioral genetics | |
| Piotrowska-Nowak et al. | New mtDNA association model, MutPred variant load, suggests individuals with multiple mildly deleterious mtDNA variants are more likely to suffer from atherosclerosis | |
| Liu et al. | Design and evaluation of a custom 50K Infinium SNP array for egg-type chickens | |
| Fujito et al. | Positive selection on schizophrenia-associated ST8SIA2 gene in post-glacial Asia | |
| Yamashita et al. | Expression quantitative trait loci analysis of 13 genes in the rat prostate | |
| Findley et al. | A signature of Neanderthal introgression on molecular mechanisms of environmental responses | |
| Sasaki et al. | New animal models reveal that coenzyme Q2 (Coq2) and placenta-specific 8 (Plac8) are candidate genes for the onset of type 2 diabetes associated with obesity in rats | |
| Zhang et al. | Novel mutations in the Myo5a gene cause a dilute coat color phenotype in mice | |
| HRP20050568A2 (en) | Haplotype partitioning | |
| Que et al. | Genetic architecture modulates diet-induced hepatic mRNA and miRNA expression profiles in diversity outbred mice | |
| Riggs et al. | Differential gene expression in epidermis of mice sensitive and resistant to phorbol ester skin tumor promotion | |
| Kumari et al. | Genetic heterogeneity in Van der Woude syndrome: identification of NOL4 and IRF6 haplotype from the noncoding region as candidates in two families | |
| CN107760790B (zh) | 一种与鸡肌肉发育相关的snp分子标记及其应用 | |
| Idigo et al. | Translation elongation factor 1A2 is encoded by one of four closely related eef1a genes and is dispensable for survival in zebrafish | |
| Phinchongsakuldit et al. | Evolution of developmental genes: molecular microevolution of enhancer sequences at the Ubx locus in Drosophila and its impact on developmental phenotypes | |
| Komata et al. | Functional involvement of multiple genes as members of the supergene unit in the female-limited Batesian mimicry of Papilio polytes | |
| HRP20050569A2 (en) | Haplotype partitioning in the proximal promoter of the human growth hormone (gh1) gene | |
| Tan et al. | Differential and correlation analyses of microarray gene expression data in the CEPH Utah families | |
| Mizutani et al. | Unique mutations in mitochondrial DNA of senescence-accelerated mouse (SAM) strains |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A1OB | Publication of a patent application | ||
| AIPI | Request for the grant of a patent on the basis of a substantive examination of a patent application | ||
| ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20071122 Year of fee payment: 5 |
|
| OBST | Application withdrawn |